U.S. drug prices are nearly four times higher than the combined average price for 11 other similar countries, according to a report released today by the House Ways and Means Committee. Committee staff analyzed 2018 pricing data for 79 drugs sold in the U.S., United Kingdom, Japan, Canada (Ontario), Australia, Portugal, France, the Netherlands, Germany, Denmark, Sweden and Switzerland. “With one exception, we found that individual drug prices in the U.S. ranged from 70% (Lantus Solostar – a type of insulin) to 4,833% (Dulera – a prescription asthma medication) higher than the combined mean price in the other 11 countries,” the report states. “Compared to individual countries, drug prices in the U.S. ranged from 0.6 to 67 times the price for the same drugs.”

Related News Articles

Headline
President Trump Friday signed three executive orders aimed at lowering the price of prescription drugs, with actions targeting federally qualified health…
Headline
The Campaign for Sustainable Rx Pricing, for which AHA is a founding member, today launched a petition and digital ad urging drug companies to suspend their “…
Headline
List prices for branded pharmaceutical products in the United States increased 159% between 2007 and 2018, an average of 9.1% per year, according to a study…
Headline
Four drugs used in hospitals for years increased their prices between 525% and 1,644% after receiving formal approval through the Food and Drug Administration’…
Headline
The Food and Drug Administration today approved the first generic albuterol sulfate inhaler to treat and prevent bronchospasms in patients with asthma or…
Headline
The Food and Drug Administration today released the first phase of its searchable Purple Book database, which includes all FDA-approved biosimilar and…